Sign In
Buy CRL
$232.51
-2.11 (-0.90%)
At Close: Jul 31, 2026
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
10:44am, Friday, 11'th Apr 2025
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
01:15pm, Thursday, 10'th Apr 2025
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy
04:51am, Tuesday, 08'th Apr 2025
Aldeyra Therapeutics' stock plummeted 74% due to an FDA Complete Response Letter for reproxalap but presents a favorable risk-reward for speculative investors. Despite past setbacks, ALDX's history of
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate
10:20am, Monday, 31'st Mar 2025
Charles River and Valo Health identify a potential therapeutic for lupus using their combined offering, Logica.
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform
08:00am, Tuesday, 25'th Mar 2025
WILMINGTON, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Valo Health announce the identification of an advanceable product candidate for treatment of lupus and othe
Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 21'st Mar 2025
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility
04:05am, Tuesday, 04'th Mar 2025
PORTO, Portugal & SAN FRANCISCO--(BUSINESS WIRE)--FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced that it had completed the acquisition of the Sout
Deciphering Charles River (CRL) International Revenue Trends
10:15am, Monday, 24'th Feb 2025
Examine the evolution of Charles River's (CRL) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance
04:58pm, Wednesday, 19'th Feb 2025
On Wednesday, Charles River Laboratories International Inc CRL reported fourth-quarter 2024 revenue of $1 billion, a decrease of 1.1% year over year, beating the consensus of $983.63 million.
Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript
03:03pm, Wednesday, 19'th Feb 2025
Charles River Laboratories International, Inc. (NYSE:CRL ) Q4 2024 Earnings Call February 19, 2025 8:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair,
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall
02:55pm, Wednesday, 19'th Feb 2025
Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments.
Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics
10:35am, Wednesday, 19'th Feb 2025
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street
Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates
09:10am, Wednesday, 19'th Feb 2025
Charles River Laboratories (CRL) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.50 per share. This compares to earnings of $2.46 per share a year ago.
Charles River beats quarterly estimates on stable demand for drug development services
08:11am, Wednesday, 19'th Feb 2025
Charles River Laboratories on Wednesday beat fourth-quarter profit and revenue estimates, helped by stable demand for its drug discovery and development services from biotech clients.
Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics
10:21am, Monday, 17'th Feb 2025
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates
